secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atrium Therapeutics, Inc. (RNA)
CIK:        0002093101
Form:       8-K
Filed at:   2026-10-08T10:52:04+00:00
Accession:  0001193125-26-417402
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Atrium Therapeutics raises $50M PIPE at $7.93/share, extending cash runway through 2028
--------------------------------------------------------------------------------

- PIPE priced at-the-market: 5,170,384 shares at $7.93 plus pre-funded warrants for 1,134,930 shares at $7.929 each (exercise price $0.001); gross proceeds ~$50M.
- Investors include Sirenia Capital Management, Aberdeen Investments, Montanova, Sessa Capital and Casdin Capital; Leerink Partners is lead placement agent with Cantor, Barclays and Wells Fargo.
- Net proceeds fund development of its two lead precision-cardiology RNA product candidates, other research programs, working capital and general corporate purposes.
- Company estimates proceeds plus existing cash fund operations through 2028; closing expected on or about October 9, 2026.
- Post-offering common shares outstanding total 22,276,027, including shares issued to settle make-whole equity awards from the Avidity Biosciences spin-off.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526417402/0001193125-26-417402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526417402/d25901d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-417402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer